ArticleScientific reports2021

Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.

Gundula Streubel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.